Prevalence and Clinicopathologic Features of HER2 Overexpression in Endocervical Adenocarcinoma
Background: Endocervical adenocarcinoma (ENCA) has poor prognosis and is increasing in developing countries. Human epidermal growth factor receptor 2 (HER2) overexpression in ENCA is not fully known. The aim of this study was to assess the prevalence and clinicopathological features of HER2 overexpr...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Shiraz University of Medical Sciences
2025-07-01
|
| Series: | Middle East Journal of Cancer |
| Subjects: | |
| Online Access: | https://mejc.sums.ac.ir/article_50530_0da249673a43159d98b69cd973ead445.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1839630886658637824 |
|---|---|
| author | Niusha Momeni Fatemeh Nili Fereshteh Ameli Soheila Sarmadi Elham Mirzaian Farnaz Moravej-Salehi Narges Zamani |
| author_facet | Niusha Momeni Fatemeh Nili Fereshteh Ameli Soheila Sarmadi Elham Mirzaian Farnaz Moravej-Salehi Narges Zamani |
| author_sort | Niusha Momeni |
| collection | DOAJ |
| description | Background: Endocervical adenocarcinoma (ENCA) has poor prognosis and is increasing in developing countries. Human epidermal growth factor receptor 2 (HER2) overexpression in ENCA is not fully known. The aim of this study was to assess the prevalence and clinicopathological features of HER2 overexpression in ENCA.Method: In this cohort study, 48 ENCA cases were reclassified using the World Health Organization (WHO) classification. Whole-tissue sections were stained for HER2 by immunohistochemistry (IHC) and scored using 2017 American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) protocol (negative= 0, 1+, equivocal= 2+, and positive= 3+). Fluorescent in situ hybridization (FISH) assay was performed for 2+ stained cases. Invasion growth pattern and clinicopathologic features were investigated. Statistical analysis was performed using Statistical Package for Social Sciences (SPSS) and Statistical software for data science (STATA) with chi square, Fischer exact, independent sample t-test, and one-way Analysis of Variance (ANOVA) at 0.05 significance level.Results: 16.6% of ENCAs overexpressed HER2, IHC3+ (n=6) and IHC2+ (n=2). No human papilloma virus (HPV)-independent case was found. HER2 was expressed in half of the invasive stratified mucin-producing carcinomas (ISMICs) (P < 0.05) and was not associated with stage, metastasis, lymph-vascular space invasion, lymph node metastasis, or pattern of invasion (P > 0.05). Conclusion: ENCAs, including HPV-associated subtypes, overexpress HER2 in about 16.6% of the cases. Overexpression in ISMIC is significantly higher than the other subtypes, which can be considered for therapeutic trials in this histopathologic subcategory. |
| format | Article |
| id | doaj-art-ada3ea86a9a6475b9dd809a80732fd14 |
| institution | Matheson Library |
| issn | 2008-6709 2008-6687 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | Shiraz University of Medical Sciences |
| record_format | Article |
| series | Middle East Journal of Cancer |
| spelling | doaj-art-ada3ea86a9a6475b9dd809a80732fd142025-07-13T04:43:08ZengShiraz University of Medical SciencesMiddle East Journal of Cancer2008-67092008-66872025-07-0116323824810.30476/mejc.2024.102620.209950530Prevalence and Clinicopathologic Features of HER2 Overexpression in Endocervical AdenocarcinomaNiusha Momeni0Fatemeh Nili1Fereshteh Ameli2Soheila Sarmadi3Elham Mirzaian4Farnaz Moravej-Salehi5Narges Zamani6Department of Pathology, Cancer Institute, Imam Khomeini Hospital Complex, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, IranDepartment of Pathology, Cancer Institute, Imam Khomeini Hospital Complex, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, IranDepartment of Pathology, Cancer Institute, Imam Khomeini Hospital Complex, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, IranDepartment of Pathology, Yas Hospital Complex, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, IranDepartment of Pathology, Dr Shariati Hospital Complex, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, IranDepartment of Pathology, Yas Hospital Complex, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, IranDepartment of Gynecology Oncology, Imam Khomeini Hospital Complex, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, IranBackground: Endocervical adenocarcinoma (ENCA) has poor prognosis and is increasing in developing countries. Human epidermal growth factor receptor 2 (HER2) overexpression in ENCA is not fully known. The aim of this study was to assess the prevalence and clinicopathological features of HER2 overexpression in ENCA.Method: In this cohort study, 48 ENCA cases were reclassified using the World Health Organization (WHO) classification. Whole-tissue sections were stained for HER2 by immunohistochemistry (IHC) and scored using 2017 American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) protocol (negative= 0, 1+, equivocal= 2+, and positive= 3+). Fluorescent in situ hybridization (FISH) assay was performed for 2+ stained cases. Invasion growth pattern and clinicopathologic features were investigated. Statistical analysis was performed using Statistical Package for Social Sciences (SPSS) and Statistical software for data science (STATA) with chi square, Fischer exact, independent sample t-test, and one-way Analysis of Variance (ANOVA) at 0.05 significance level.Results: 16.6% of ENCAs overexpressed HER2, IHC3+ (n=6) and IHC2+ (n=2). No human papilloma virus (HPV)-independent case was found. HER2 was expressed in half of the invasive stratified mucin-producing carcinomas (ISMICs) (P < 0.05) and was not associated with stage, metastasis, lymph-vascular space invasion, lymph node metastasis, or pattern of invasion (P > 0.05). Conclusion: ENCAs, including HPV-associated subtypes, overexpress HER2 in about 16.6% of the cases. Overexpression in ISMIC is significantly higher than the other subtypes, which can be considered for therapeutic trials in this histopathologic subcategory.https://mejc.sums.ac.ir/article_50530_0da249673a43159d98b69cd973ead445.pdfuterine cervical neoplasmsher2 proteinimmunohistochemistryprognosis |
| spellingShingle | Niusha Momeni Fatemeh Nili Fereshteh Ameli Soheila Sarmadi Elham Mirzaian Farnaz Moravej-Salehi Narges Zamani Prevalence and Clinicopathologic Features of HER2 Overexpression in Endocervical Adenocarcinoma Middle East Journal of Cancer uterine cervical neoplasms her2 protein immunohistochemistry prognosis |
| title | Prevalence and Clinicopathologic Features of HER2 Overexpression in Endocervical Adenocarcinoma |
| title_full | Prevalence and Clinicopathologic Features of HER2 Overexpression in Endocervical Adenocarcinoma |
| title_fullStr | Prevalence and Clinicopathologic Features of HER2 Overexpression in Endocervical Adenocarcinoma |
| title_full_unstemmed | Prevalence and Clinicopathologic Features of HER2 Overexpression in Endocervical Adenocarcinoma |
| title_short | Prevalence and Clinicopathologic Features of HER2 Overexpression in Endocervical Adenocarcinoma |
| title_sort | prevalence and clinicopathologic features of her2 overexpression in endocervical adenocarcinoma |
| topic | uterine cervical neoplasms her2 protein immunohistochemistry prognosis |
| url | https://mejc.sums.ac.ir/article_50530_0da249673a43159d98b69cd973ead445.pdf |
| work_keys_str_mv | AT niushamomeni prevalenceandclinicopathologicfeaturesofher2overexpressioninendocervicaladenocarcinoma AT fatemehnili prevalenceandclinicopathologicfeaturesofher2overexpressioninendocervicaladenocarcinoma AT fereshtehameli prevalenceandclinicopathologicfeaturesofher2overexpressioninendocervicaladenocarcinoma AT soheilasarmadi prevalenceandclinicopathologicfeaturesofher2overexpressioninendocervicaladenocarcinoma AT elhammirzaian prevalenceandclinicopathologicfeaturesofher2overexpressioninendocervicaladenocarcinoma AT farnazmoravejsalehi prevalenceandclinicopathologicfeaturesofher2overexpressioninendocervicaladenocarcinoma AT nargeszamani prevalenceandclinicopathologicfeaturesofher2overexpressioninendocervicaladenocarcinoma |